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ABSTRACT
Objectives: To study the number of patients that
taper or discontinue concomitant methotrexate (MTX)
in daily practice in patients with rheumatoid arthritis
(RA) treated with tumour necrosis factor inhibitor
(TNFi) and to analyse the effects of that adaption on
disease activity and drug survival.
Methods: Data were collected from the Dutch
Rheumatoid Arthritis Monitoring (DREAM) registry.
Patients who started their first TNFi were included in
the study. Treatment effectiveness after MTX tapering
or discontinuation was analysed using Disease Activity
Score of 28 joints (DAS28). Drug survival of the TNFi
was analysed using the Cox proportional hazard model
with a time-dependent covariate.
Results: In 458 patients (34%), MTX was tapered,
126 patients (10%) discontinued MTX and 747
patients (56%) continued MTX at the same dose. On
average, DAS28 improved after tapering MTX (−0.40,
−0.45) and after stopping MTX (−0.28, −0.12) at 6
and 12 months. In the taper group, 21% of the
patients relapsed (DAS28 increase >0.6), and in the
discontinuation group this was 21% and 24% at 6 and
12 months, respectively. Patients who taper and
discontinue MTX have a similar DAS28 score over time
as patients who continue MTX. Moreover, there was no
influence of tapering or discontinuation of MTX on
long-term drug survival of TNFi.
Conclusions: In daily practice, tapering or
discontinuation of concomitant MTX in patients with
RA treated with TNFi frequently occurs and it does not
seem to influence the average DAS28 over time or the
long-term TNFi drug survival. It appears that in daily
clinical practice the correct patients are selected to
taper or discontinue MTX.
INTRODUCTION
Insufﬁcient effect of methotrexate (MTX) is
most often the reason to add a tumour necro-
sis factor inhibitor (TNFi) to the treatment
strategy of patients with rheumatoid arthritis
(RA). The combination of TNFi with MTX
provides better results than TNFi monother-
apy1–3 and is therefore recommended in clin-
ical guidelines.4 However, MTX can cause
mild adverse events like gastrointestinal pro-
blems in about 50% of the patients, with
nausea as the main symptom. Also, head-
aches, dizziness and oral ulcers are often
heard symptoms.5 6 This observation ﬁts with
the clinical experience that treatment with
MTX is often a burden for patients. Owing to
this burden, it might be the patient’s wish to
taper or discontinue MTX when the combin-
ation with TNFi results in signiﬁcant improve-
ments rather than taper or discontinue TNFi.
However, no data are available whether or not
Key messages
What is already known about this subject?
▸ Tumour necrosis factor inhibitor (TNFi) is more
effective in combination with methotrexate
(MTX), but 50% of patients with rheumatoid
arthritis (RA) experience discomfort/inconveni-
ence due to adverse events of the MTX.
What does this study add?
▸ MTX is tapered and discontinued in daily prac-
tice in patients with RA using TNFi with con-
comitant MTX. + Tapering or discontinuation
concomitant MTX has on average no negative
effects on DAS28 scores or on long-term TNFi
drug survival.
How might this impact on clinical practice?
▸ The correct patients were chosen to taper and
discontinue concomitant MTX in daily practice.
In these and perhaps also other patients, the
discomfort/inconvenience of the adverse events
of MTX can be reduced and therefore the quality
of life can be increased.
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concomitant MTX can be tapered or discontinued in
daily clinical practice. Therefore, the objective of this
study was to explore how frequently MTX is tapered or
discontinued in daily clinical practice and the effects of
that on disease activity in the short term, and on the
TNFi drug survival in the long term.
PATIENTS AND METHODS
Design
This is a cohort study using data from the biologic register
of the Dutch Rheumatoid Arthritis Monitoring (DREAM)
project. Since February 2003, all patients with RA who
started on one of the biological agents for the ﬁrst time in
one of 12 centres in the Netherlands have been included
in the DREAM biologic register. Patients in this study were
not randomised to a speciﬁc treatment and data collection
continued even when patients stopped using biological
agents. Since the study protocol is in line with the advice
on safety and effectiveness monitoring of the Dutch guide-
line for diagnosis and treatment of patients with RA, this
register does not need extended ethical approval. This was
conﬁrmed by the regional ethical committee Arnhem-
Nijmegen. Patients signed informed consent on gathering
their data in an electronic database and using their data
for research purposes.
Inclusion/exclusion criteria
All patients had a diagnosis of RA according to the 1987
American College of Rheumatology classiﬁcation criteria7
and a Disease Activity Score of 28 joints (DAS28) >3.2.
Prior treatments with at least two other disease-modifying
antirheumatic drugs (DMARDs) including MTX and
absence of an absolute contraindication for a TNFi (eg,
pregnancy, presence of a serious infection) were required.
Inclusion criteria for the DREAM biologic registry were
based on the Dutch regulations for reimbursement.
Assessments
Patients were assessed at the start of TNFi treatment
(baseline) and every 3 months thereafter. The following
baseline measurements were collected: age, gender,
rheumatoid factor (RF), disease duration (since the
time of diagnosis), presence of erosive disease, previous
and/or current antirheumatic treatment, DAS28,8
Health Assessment Questionnaire Disability Index
(HAQ-DI)9 and medication consumption. The clinical
assessments used to determine DAS28 were performed
by trained nurses, and the HAQ-DI was completed by
the patients themselves. DAS28, HAQ-DI, medication
history and the presence of comorbidities were reas-
sessed at the scheduled clinical visits.
Statistical analyses
For this study, patients with RA and using their ﬁrst
TNFi with concomitant MTX were eligible for the ana-
lyses. First, the percentages of patients who tapered and
discontinued MTX were analysed. Patients who tapered
MTX during the TNFi treatment were included in the
taper group. Patients who stopped MTX directly, without
tapering ﬁrst, were included in the discontinuation
group. All other patients were analysed in the continu-
ation group. Second, comparisons between these three
groups were analysed. The intention-to-treat principal
was used for these analyses.
To detect baseline differences in age, gender, RF posi-
tivity, presence of erosions, disease duration, type of
TNFi treatment, amount of previous DMARDs, DAS28 at
baseline, HAQ-DI at baseline and co-medication, univari-
ate analyses of baseline variables were performed using
analysis of variance, a Kruskal-Wallis test and a χ2 test,
depending on the distribution and type of data.
Patient characteristics were compared between those
who had a relapse (deﬁned as an increase in disease activ-
ity >0.6 on DAS28)10 and those who did not have a
relapse by using a t-test, a Mann-Whitney U test and a χ2
test, as appropriate. The change in DAS28 scores at 6 and
12 months after tapering and discontinuation of MTX
was calculated. Patients with missing DAS28 data at base-
line or the follow-up measurement could not be
included. Linear mixed models with the interaction term
between time and tapering MTX (yes/no) were used to
analyse if the course of DAS28 over time is different in
the MTX taper group compared to the patients who dis-
continued MTX and continued MTX. Using the linear
mixed model approach for the repeated measures within
the patients has the advantage that all available data
could be used despite some missing values.11 The missing
data are assumed to be missing at random. For the mixed
model analyses, the ﬁrst-order autoregressive (AR(1))
covariance structure was used. This structure was the best
ﬁt for these outcome measures (−2 restricted log likeli-
hood). To analyse if there is a difference in long-term
drug survival of TNFi between the groups, Cox propor-
tional hazard modelling was used in which the time till
tapering and discontinuation was deﬁned as a time-
dependent covariate. A hazard ratio signiﬁcantly higher
than one means that the patients who discontinue or
taper have worse TNFi drug survival than those in the
continuation group. In the mixed model and Cox regres-
sion analyses, a correction was made for all possible con-
founders. Patients using golimumab and certolizumab
could not be taken into account because the number of
patients in these groups were too small.
RESULTS
Between February 2003 and June 2012, a total of 1933
patients with RA started their ﬁrst TNFi therapy.
Sixty-nine per cent (1331/1933) of these patients used
TNFi in combination with MTX. For the patients treated
with inﬂiximab, the percentage of MTX users was 71, for
patients treated with adalimumab the percentage was 72,
and for patients treated with etanercept this was 66%.
Table 1 shows the clinical characteristics of patients in
whom MTX was tapered and discontinued during
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treatment with TNFi and of patients who continued
MTX. The patients who tapered had a less number of
previous DMARDs and higher MTX doses than patients
who continued and discontinued MTX.
Tapering of MTX
There were 34.4% (458/1331) patients with concomi-
tant MTX in whom MTX was tapered during follow-up.
In half of the patients, the dose was tapered within
6 months (median=149 days (IQR 84–325)) after the
start of their TNFi. MTX tapering occurred in 33% of
the patients using inﬂiximab, in 38% of patients using
adalimumab, and in 35% of patients using etanercept.
Most patients who tapered MTX had a dose of 25 mg
MTX at the start: 50%. After this ﬁrst MTX dose taper-
ing, 41.3% (189) patients tapered their MTX dose
further (median=180 days (IQR 91–354)) and 12.2%
(56) increased their MTX dose again (median=99 days
(IQR 77–240)).
Table 2 presents the effects after tapering MTX at the
group level. The average DAS28 score after MTX taper-
ing decreased at 6 and 12 months.
Relapse rates
In 21% of the patients, DAS28 increased more than 0.6
at 6 and 12 months, table 2. Patients who relapsed at
6 months had signiﬁcantly (p=0.004) more patients on
<10 mg MTX after tapering (19.1%) than patients who
did not relapse (7.4%). Moreover, DAS28 at the time of
taper was lower (mean difference=1.20, p<0.001), the
patients tapered later in time (mean difference=77 days,
p=0.003), they used more previous DMARDs in the past
(p=0.009) and had lower MTX doses before taper
(p=0.016) in patients who relapsed compared to those
who did not. At 12 months, patients who relapsed had
lower DAS28 scores at the moment of taper (mean dif-
ference=1.25, p<0.001).
Discontinuation of MTX
In 9.5% (126/1331) of the patients, MTX was discontin-
ued during follow-up. Half of those patients did so within
9 months (median=261 days (IQR 97–552)) after the
start of their TNFi. MTX discontinuation occurred in
7.8% of the patients using inﬂiximab, in 8.7% of patients
using adalimumab, and in 10.3% of patients using etaner-
cept. The largest group of patients used 15 mg of MTX
before discontinuation (30.6%). Those patients discon-
tinuing their MTX treatment had an average DAS28 at
discontinuation of 3.6 (SD=1.4). The improvement in
DAS28 at 6 and 12 months was 0.28 and 0.12, respectively.
Relapse rates
Six and 12 months after discontinuation of MTX, a >0.6
increase in DAS28 was observed in 21% and 24%,
Table 1 Patients’ characteristics at start of the TNFi treatment
Discontinue
(N=126) Taper (N=458) Continue (N=747) p Value
Mean age in years (SD) 53 (13) 54 (12) 56 (13) 0.061
Female gender in % 60 69 67 0.201
RF positive in % 68 73 67 0.063
Presence of erosions in % 59 67 59 0.054
Median disease duration in years (IQR) 4 (1–12) 4 (2–11) 5 (2–11) 0.770
Mean DAS28 (SD) 4.9 (1.2) 4.8 (1.4) 4.9 (1.3) 0.764
Mean HAQ-DI (SD) 1.3 (0.6) 1.3 (0.7) 1.3 (0.6) 0.441
Median MTX dose in mg (IQR) 15 (15–25) 25 (20–25) 15 (10–25) 0.000
<10 18.2 1.3 8.3
10–17.5 46.3 21.4 31.6
20–30 33.9 77.1 58.8
>30 1.7 2.2 1.2
Type of TNFi in % (n) 0.079
Adalimumab 38.1 (48) 44.3 (203) 40.3 (301)
Etanercept 50.0 (63) 44.8 (205) 46.2 (345)
Infliximab 9.5 (12) 10.9 (50) 12.3 (92)
Certolizumab pegol 0 (0) 0 (0) 0.4 (3)
Golimumab 2.4 (3) 0 (0) 0.8 (6)
Median number of previous DMARDs (IQR) 3 (2–4) 3 (2–3) 3 (2–4) 0.043
Number of present DMARDs* in % (n) 0.107
1 70.6 (89) 73.4 (336) 66.1 (494)
2 27.0 (34) 24.0 (110) 30.0 (224)
<2 2.4 (3) 2.6 (12) 3.8 (28)
*These are without prednisone; prednisone was prescribed for 28% in the discontinuation group; for 25% in the taper group and for 31% in
the continuation group.
Bold typeface indicates significance at p<0.05.
DAS28, Disease Activity Score of 28 joints; DMARDs, disease-modifying antirheumatic drugs; HAQ-DI, Health Assessment Questionnaire
Disability Index; MTX, methotrexate; RF, rheumatoid factor; TNFi, tumour necrosis factor inhibitor.
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respectively, of the patients (see table 2). There were no
signiﬁcant differences in patient characteristics in
patients who relapsed and those who did not.
DAS28 course over time
DAS28 over time from start of the TNFi treatment was eval-
uated with linear mixed models between discontinuation,
tapering and continuation (ﬁgure 1). The results show
that patients who taper have the lowest DAS28 over time.
However, the three groups all have the same course over
time after the initial improvement in DAS28. The inter-
action between taper (yes or no) and time (follow-up in
months) is not signiﬁcantly different (β=0.006; CI −0.001
to 0.013, p=0.071). The same accounts for the interaction
between discontinuation and time (β=0.002; CI −0.008 to
0.013, p=0.660). (See ﬁgure 1).
TNFi drug survival
The long-term drug survival is signiﬁcantly different
between the patients tapering and the patients continu-
ing with a hazard rate (Hr) of 0.744 (0.606 to 0.913;
table 3). This means that patients’ risk of stopping TNFi
decreased by 25.6% if patients tapered their MTX treat-
ment. So, even with correction for the time-dependent
variable of time of tapering MTX and other confound-
ing factors, patients who taper MTX have a better drug
survival of TNFi. The long-term drug survival of the
TNFi is not signiﬁcantly different between patients who
discontinued MTX and patients who continued MTX
(Hr=1.046; CI 0.760 to 1.440; p=0.783) (table 4).
DISCUSSION
The main objective of this observational study was to
evaluate how many patients with RA treated with TNFi
and concomitant MTX taper or discontinue their MTX.
Table 2 Change (in DAS28) after tapering and stopping MTX
Discontinue Taper






From injection to tablet* – 2.1




Reasons to taper or discontinue in %
Low disease activity or remission 15.1 59.6
Side effects 61.9 23.8
Ineffectiveness 8.7 1.7
Other reason 6.3 9.4
Unknown 7.9 5.5
Mean DAS28 at taper or discontinuation (SD) 3.6 (1.4) 3.4 (1.5)
Mean DAS28 difference at 6 months after taper or discontinuation (SD) −0.28 (1.45) −0.40 (1.32)
Mean DAS28 difference at 12 months after taper or discontinuation (SD) −0.12 (1.46) −0.45 (1.43)
Patients with relapse† at 6 months after taper or discontinuation in % 21 21
Patients with relapse† at 12 months after taper or discontinuation in % 24 21
*Switch from MTX injection to MTX tablet intake.
†Relapse is defined as an increase in DAS28 of >0.6.
−, Not applicable for this group.
DAS28, Disease Activity Score of 28 joints; MTX, methotrexate.
Figure 1 Predicted DAS28 scores over time from start with
TNFi, separately for patients that discontinue, taper and
continue MTX.
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In addition, we analysed the effect on disease activity
and long-term TNFi drug survival of tapering or discon-
tinuation of MTX. This study revealed that 34.4% of the
patients starting with TNFi plus MTX taper their MTX
treatment and 9.5% discontinue MTX. After tapering
and discontinuation of MTX, the mean DAS28 score
even decreased and the long-term drug survival of the
TNFi was not worse from patients that continued. The
TNFi drug survival of the taper group even tends to be
better than that in the continuation group.
The number of patients who tapered or discontinued
MTX in our cohort study was somewhat lower than in
the study of Kremer et al.12 In the study by Kremer
et al,12 62% of the patients decreased or discontinued
MTX in patients with RA that used etanercept with
MTX. These patients were ﬁrst included in a 12-month
clinical trial where concomitant medication could not
be adapted. In those patients who decreased or discon-
tinued MTX, the response to etanercept was main-
tained. With respect to the effectiveness also, other
studies showed more or less consistent results, although
these studies had other outcomes and only studied
inﬂiximab in combination with MTX.13 14 In the clinical
trial of Klarenbeek et al,13 MTX was tapered and discon-
tinued in patients in remission (DAS <1.6) for more
than 6 months. If the DAS level increased over 1.6, the
MTX/DMARD was reintroduced. Thirty-six of 128
patients starting inﬂiximab with MTX were DMARD
drug free at one point in time and 21 patients were still
DMARD drug free after 5 years. The study of
Fleischmann et al14 showed that 76% of the patients had
40% improvement in the combined tender and swollen
joint count at week 22 after starting inﬂiximab with
MTX. In these patients, the MTX dose was decreased
from 15 to 5 mg. In 79% of the responders, this tapering
of MTX did not increase the disease activity. On the con-
trary, the Canadian randomised trial of Pope et al15
showed an increase of DAS28 after discontinuation of
MTX. These results are different from our non-con-
trolled setting, and it is possible that in our daily practice
the correct patients are selected to taper or discontinue
MTX.
This study has some limitations that should be men-
tioned. The ﬁrst limitation is the possible confounding
by indication due to the study design. These were cor-
rected for all measured confounders; however, in add-
ition other, unmeasured factors might differ between
the groups. Although it is good to see the differences
between patients who taper, discontinue and continue
MTX, the comparison between the groups should be
carefully interpreted. Second, it was not possible to dif-
ferentiate between TNFi treatments in the analyses in
the patients who discontinued MTX. Here, the number
of patients with complete data was too small to make
valid conclusions. Moreover, the difference in patients
characteristics in patients that relapsed compared to
patients that did not relapse in the discontinuation
group are performed on small amounts of patients. This
could be a reason why no signiﬁcant differences were
found between those groups. Also, other analyses in sub-
groups, like different doses of MTX, will not result in
valid conclusions due to the small number of patients.
By studying our observational data, some remarkable
results were found that need some discussion. On the
basis of the literature that TNFi in combination with
MTX provides better drug survival,16 17 we hypothesised
that if patients tapered their MTX, they would have a
worse drug survival of the TNFi. This does not seem to
be the case. Despite the correction for the time-
dependent variable, the start of tapering MTX, the long-
term drug survival is still better in the patients who
taper MTX. Perhaps this is because the patients still use
a low dose of MTX and only a small percentage <10 mg
MTX. Burmester et al18 show in a clinical trial that TNFi
plus 20 mg MTX provides the same results as TNFi plus
Table 4 Cox proportional regression hazard model with
time-dependent covariate
HR (95% CI) p Value
Discontinuation of MTX 1.046 (0.760 to 1.440) 0.783
Female gender 0.930 (0.750 to 1.155) 0.512
RF positive 0.841 (0.660 to 1.073) 0.164
Erosions present 1.493 (1.185 to 1.880) 0.001
Age 0.998 (0.989 to 1.006) 0.557
Disease duration 0.998 (0.984 to 1.013) 0.787
Co-medication 1.055 (0.870 to 1.281) 0.585
Number of previous
DMARDs
1.002 (0.914 to 1.098) 0.973
TNFi
Infliximab (ref) 0.000
Adalimumab 0.584 (0.441 to 0.774) 0.000
Etanercept 0.384 (0.289 to 0.512) 0.000
DMARDs, disease-modifying antirheumatic drugs; MTX,
methotrexatel; ref, reference variable; RF, rheumatoid factor; TNFi,
tumour necrosis factor inhibitor.
Table 3 Cox proportional regression hazard model with a
time-dependent covariate
HR (95% CI) p Value
Taper MTX 0.744 (0.606 to 0.913) 0.005
Female gender 1.048 (0.662 to 1.268) 0.628
RF positive 0.922 (0.748 to 1.137) 0.448
Erosions present 1.393 (1.144 to 1.697) 0.001
Age 0.996 (0.989 to 1.003) 0.250
Disease duration 1.001 (0.988 to 1.014) 0.874
Co-medication 1.028 (0.866 to 1.220) 0.751
Number of previous
DMARDs
1.048 (0.965 to 1.138) 0.265
TNFi
Infliximab (ref) 0.000
Adalimumab 0.519 (0.406 to 0.662) 0.000
Etanercept 0.407 (0.317 to 0.522) 0.000
DMARDs, disease-modifying antirheumatic drugs; MTX,
methotrexate; ref, reference variable; RF, rheumatoid factor; TNFi,
tumour necrosis factor inhibitor.
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10 mg, and similar ﬁndings are presented in daily
clinical practice.19 Another explanation can be that
the patients who taper or discontinue MTX are correctly
chosen by the rheumatologists to taper MTX and
are ‘better’ patients who generally respond better to
treatment. The latter can perhaps also explain the
remarkable ﬁnding that DAS28 still decreases after
tapering or stopping MTX. Another possible explan-
ation is that there is still some effect of the TNFi treat-
ment, so the decrease in DAS28 is due to the effect of
the TNFi. This can also explain why the patients who
taper the MTX more early respond better to the taper-
ing of the MTX.
Now that we know that it is possible to taper and even
discontinue MTX when patients start with TNFi, the
question is: In which patients is this possible?
Unfortunately, there were no clear patient characteristics
that have an association with patients who relapse or
not. Tapering later and lower MTX doses were asso-
ciated with relapse. Also, lower DAS28 scores at the
moment of tapering or discontinuation were associated
with relapse. This is in contrast with the TNFi stopping
and tapering studies. An explanation for this might be
the differences in patient populations: in the TNFi
studies, tapering or stopping is being done in patients
who reached a state of remission (DAS28 <2.6) or low
disease activity (DAS28 <3.2), while in our study no
formal criteria for disease activity were present; in add-
ition also, for instance, intolerance was a reason for stop-
ping/tapering. As a result of this, the disease activity at
the moment of stopping/tapering was moderate: mean
DAS28 of 3.4. A future randomised clinical trial would
perhaps be able to investigate if tapering MTX is pos-
sible for all patients who have a good response to TNFi
treatment with concomitant MTX or in patients in
whom the MTX can be discontinued or tapered best.
The question if biological treatments can be tapered or
discontinued is nowadays also interesting because of the
possible reduction in costs. So how do we deal with this
in daily practice? A possibility would be to taper bio-
logical treatment if patients are in remission and can tol-
erate their current MTX dose well. However, if patients
experience inconvenience from the MTX treatment, or
remission is not reached, MTX could be tapered. If
patients tapered their MTX dose to a tolerated dose and
they are still in remission, perhaps it is possible to taper
the TNFi after all. If we want to increase the quality of
the patients’ lives, tapering or discontinuing MTX can
be interesting in patients who experience inconvenience
from MTX treatment. In cost-effectiveness analysis, the
effects are usually expressed in quality of life years and
these are compared with the costs. The comparison of
cost-effectiveness between tapering TNFi and tapering
MTX in patients starting that combination would be an
interesting research question for future research.
In daily practice, patients with RA do taper and dis-
continue their MTX dose. This does not seem to inﬂu-
ence DAS28 over time or the long-term TNFi drug
survival, which might indicate that in daily practice the
physicians selected the correct patients to taper or dis-
continue MTX treatment. In these patients, the discom-
fort/inconvenience of the MTX use can be reduced.
However, it is difﬁcult to generalise these ﬁndings to all
patients starting TNFi with MTX treatment, because the
reason to choose specially these patients is unknown. To
study in which patients MTX can be tapered and discon-
tinued, other and larger studies should be performed.
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